Patriot Financial Group Insurance Agency LLC Raises Stake in AbbVie Inc. $ABBV

Patriot Financial Group Insurance Agency LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 184.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,249 shares of the company’s stock after purchasing an additional 9,242 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in AbbVie were worth $3,299,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Hobart Private Capital LLC increased its position in shares of AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after acquiring an additional 48 shares during the period. Rise Advisors LLC boosted its holdings in shares of AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock valued at $336,000 after purchasing an additional 48 shares during the period. Sivia Capital Partners LLC grew its stake in AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock worth $848,000 after purchasing an additional 51 shares in the last quarter. FF Advisors LLC increased its holdings in AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares during the period. Finally, Landaas & Co. WI ADV increased its holdings in AbbVie by 1.1% during the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of AbbVie stock opened at $222.87 on Friday. The company has a market capitalization of $393.89 billion, a PE ratio of 168.84, a P/E/G ratio of 1.27 and a beta of 0.36. The company has a 50-day simple moving average of $226.70 and a two-hundred day simple moving average of $210.69. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business earned $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent research reports. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. BMO Capital Markets increased their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.